tradingkey.logo
搜尋

enVVeno Medical Corp

NVNO
添加自選
9.810USD
-0.040-0.42%
收盤 05/15, 16:00美東報價延遲15分鐘
6.55M總市值
虧損本益比TTM

enVVeno Medical Corp

9.810
-0.040-0.42%
查看詳細走勢圖
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.42%

5天

-1.31%

1月

-14.40%

6月

-33.27%

今年開始到現在

-12.63%

1年

+170.99%

TradingKey enVVeno Medical Corp股票評分

單位: USD 更新時間: 2026-05-15

操作建議

enVVeno Medical Corp當前公司基本面數據相對謹慎,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名215/382位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為12.50。中期看,股價處於平穩狀態。近一個月,市場表現非常差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

enVVeno Medical Corp評分

相關信息

行業排名
215 / 382
全市場排名
453 / 4482
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

enVVeno Medical Corp亮點

亮點風險
enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
估值高估
公司最新PE估值-0.01,處於3年歷史高位
機構減倉
最新機構持股184.36K股,環比減少34.20%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉1.47K股

分析師目標

基於 1 分析師
持有
評級
12.500
目標均價
+1517.29%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

enVVeno Medical Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

enVVeno Medical Corp簡介

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
公司代碼NVNO
公司enVVeno Medical Corp
CEOBerman (Robert A)
網址https://envveno.com/
KeyAI